HDAC Inhibitor Combination With Chemoimmunotherapy in the Neoadjuvant Treatment of pMMR Locally Advanced Colon Cancer

HDAC Inhibitor Combination With Chemoimmunotherapy in the Neoadjuvant Treatment of pMMR Locally Advanced Colon Cancer is a phase 2, randomised interventional study registered as NCT06709885 by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, with a registry enrolment figure of 100 participants, started 2024-10-15 and due to reach its primary completion in 2025-09-30. Interventions recorded: Chidamide + Tislelizumab + chemotherapy (CapeOX ); CapeOX. Conditions listed: Colon Adenocarcinoma. Primary outcome: pCR. Colorectal eligibility wording from the registry: "Patients with colon cancer who are assessed by abdominal contrast-enhanced CT/abdominopelvic MRI as high-risk T3 (tumor destroys muscle wall and extends to pericolonic fat, protruding more than 5 mm into adjacent mesenteric fat) or T4 (tumor penetrates the visceral peritoneal surface or directly inv". Sites: China. No results are recorded here; the registry entry is the source.